Could Future Type 1 Diabetes Treatment Target the Immune System Instead of Just Blood Sugar?

Scientists are exploring an experimental antibody strategy designed to protect insulin-producing pancreatic cells

Type 1 diabetes has traditionally been viewed through the lens of insulin deficiency: when pancreatic β-cells are destroyed, the body can no longer produce enough insulin, making insulin replacement essential.

But what if future treatment could go one step earlier?

What if scientists could protect the insulin-producing cells from the autoimmune processes that destroy them in the first place?

Researchers at Johns Hopkins are investigating an intriguing experimental approach that could move Type 1 diabetes treatment closer to its underlying biology.

 A different way of thinking about Type 1 diabetes

Type 1 diabetes is an autoimmune disease. The body's immune system mistakenly attacks insulin-producing β-cells in the pancreas.

Current treatment focuses primarily on replacing the insulin the body can no longer produce and carefully managing blood glucose.

The Johns Hopkins research takes a different approach: protect the β-cells themselves.

Researchers investigated an experimental humanized antibody called Isle43, which targets a protein known as zinc transporter 8 (ZnT8) found on pancreatic insulin-producing cells.

ZnT8 is already known to be associated with Type 1 diabetes and autoimmune responses against β-cells.

 What does the antibody do?

The researchers found that the antibody can bind to ZnT8 and enter β-cells.

In experimental models, this appeared to influence several biological processes associated with β-cell stress and immune recognition.

The researchers reported reductions in inflammatory and cellular stress, changes in HLA class-I expression, and increases in the immune-regulatory molecule PD-L1.

The broader idea is fascinating:

Rather than broadly suppressing the immune system, could scientists selectively protect the cells that are being attacked?

 Promising results—but still early

One of the most interesting findings came from experiments involving NOD mice, an established animal model of autoimmune diabetes.

Treatment with Isle43 produced a dose-dependent reversal of newly developed diabetes in these mice, with remission continuing after treatment was discontinued.

The researchers also investigated human pancreatic islet grafts in mice and observed protective effects.

These findings are encouraging—but there is a major distinction that should not be overlooked.

This is still preclinical research.

The results do not mean that people with Type 1 diabetes can currently receive this antibody as a treatment.

Animal studies frequently produce promising results that require substantial additional testing before a therapy can be considered safe and effective in humans.

Human clinical trials will ultimately be needed to determine whether this strategy can work in patients.

 Why could this matter?

The research illustrates an important shift occurring in diabetes science.

Instead of thinking only about:

“How can we replace the insulin?”

researchers are increasingly asking:

“How can we preserve or restore the cells that make insulin—and prevent the immune system from destroying them?”

That could eventually open the door to more precise therapies aimed at the biological mechanisms driving Type 1 diabetes.

The long-term future may involve combinations of approaches including:

Immune modulation

β-cell protection

Islet transplantation

Stem-cell-derived β-cell replacement

Regeneration of insulin-producing cells

Continuous glucose monitoring and advanced insulin delivery

 What patients should know

This research should be viewed as promising science, not a new cure.

People living with Type 1 diabetes should not stop insulin or change their treatment because of experimental research.

Insulin remains essential for people whose bodies cannot produce sufficient insulin.

The significance of this study is that it could help researchers develop therapies that intervene closer to the underlying autoimmune process.

 The bigger picture

The future of Type 1 diabetes treatment may eventually be less about simply managing the consequences of β-cell destruction and more about preventing or reversing the destruction itself.

That would represent a major change in the way we approach the disease.

For now, however, the journey from laboratory research to an approved human treatment remains long.

But the scientific question is becoming increasingly exciting:

What if we could protect the pancreatic cells before the immune system destroys them?

That is one of the questions researchers are now trying to answer.

Vion Pharma | Health • Medicine • Wellness

Educational content only. This article discusses experimental preclinical research and is not medical advice.